Highly Experienced Pharmaceutical Consultant who has led manufacturing and supply teams for over 30 years.

Beth Lindsey has led international teams responsible for sourcing products worth some $4bb in revenues from Pharma, OTC, and Biotech contract manufacturers across the globe.

Her expertise includes strategic analysis and rationalization of large contract supply networks, strategic sourcing and contract negotiation. Her 30 years in the industry has given her a deep knowledge of contract manufacturing offerings and contacts, resulting in her ability to pinpoint the right manufacturer for a client’s specific needs. She has extensive experience in supplier relationship management and creation of performance improvement plans to allow a CMO to respond rapidly to a client’s business requirements.

In addition, she has been integrally involved in both the acquisition and divestment of Pharma products from Phase II to products nearing the end of their life-cycle including authorized generics. She has led projects from initial due diligence to contract development and negotiation to final logistics and integration into the receiving company. Under her leadership, her divisions have successfully integrated acquired companies’ supply networks.

Beth has an MS degree in Industrial Engineering and Operations Research from North Carolina State University. She is a Green Belt in Lean Manufacturing and Six Sigma.

Examples of projects completed:

  • Accelerated launch of a new product in the US market following NDA approval
  • Supply Chain management for small pharmaceutical company
  • Product Technical Due Diligence for virtual pharmaceutical company
  • Integration of acquired products into small Pharma companies supply management processes and system
  • Contract manufacturing partner selection for a multinational consumer health company
  • Supply agreement negotiation for virtual company with product in Phase III
  • Designed and set up organization as virtual factory with planning, financial, quality, supply and technical personnel operating under single systems platform.
  • Accountable for supply from some 70+ external sites in network which delivered product worth up to $4bb, approximately 20% of all GSK US revenue.
  • Accountable for GEK activity for in-licensing new products that originated with third party suppliers in N. America, including deal set up and new product introduction product management.
  • Launched products worth over $2bb in revenues including Wellbutrin XL
  • Responsible for CMO portion of Stiefel integration into GSK as well as integration of $1.3bb Reliant Pharmaceuticals acquisition